scispace - formally typeset
A

Ashley K Clift

Researcher at University of Oxford

Publications -  51
Citations -  1135

Ashley K Clift is an academic researcher from University of Oxford. The author has contributed to research in topics: Neuroendocrine tumors & Population. The author has an hindex of 14, co-authored 48 publications receiving 580 citations. Previous affiliations of Ashley K Clift include Imperial College London.

Papers
More filters
Journal ArticleDOI

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.

TL;DR: In this article, the authors examined the risks of severe COVID-19-related hospitalisation, admission to ICU, and death in relation to respiratory disease and use of inhaled corticosteroids, adjusting for demographic and socioeconomic status and comorbidities associated with severe CoV-19.
Journal ArticleDOI

Therapeutic strategies for neuroendocrine liver metastases.

TL;DR: A wide panel of treatment options exists for these patients as mentioned in this paper, however, there is uncertainty with regard to the optimal treatment regimens and the current knowledge pertaining to these treatment options is analyzed.
Journal ArticleDOI

COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults.

TL;DR: A study that evaluates Down syndrome as a risk factor for death from COVID-19 through a comprehensive analysis of individual-level data in a cohort study of 8 26 million adults is offered.
Journal ArticleDOI

Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort.

TL;DR: In this paper, a large-scale observational and Mendelian randomisation (MR) analysis using UK Biobank data was conducted to estimate associations between smoking status and confirmed SARS-CoV-2 infection, COVID-19-related hospitalisation, and COVID -related death.
Journal ArticleDOI

Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

TL;DR: An outlook of the future in these tumour types will include the development of precision oncology frameworks for individualised therapy, multi-analyte predictive biomarkers, artificial intelligence-derived clinical decision support tools and elucidation of the role of the microbiome in NEN development and clinical behaviour.